MYGN Q2 2017 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q2 2017 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$201M+7.5% YoY

Gross Profit

$158M78.8% margin

Operating Income

$17M8.5% margin

Net Income

$13M6.4% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

+1.8%

Cash Flow

Operating Cash Flow

$37M

Free Cash Flow

$36M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$447M

Stockholders' Equity

$778M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$201M	$187M	+7.5%
Gross Profit	$158M	$147M	+7.8%
Operating Income	$17M	$36M	-52.1%
Net Income	$13M	$23M	-44.9%

Revenue Segments

Diagnostics

$188M94%

All Other Segments

$13M6%